Panbela Therapeutics Inc (OTCPK:PBLA)
$ 0.37 0.01 (2.78%) Market Cap: 1.80 Mil Enterprise Value: 8.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100
Back to the Transcripts List

Q3 2024 Panbela Therapeutics Inc Earnings Call Transcript

Nov 14, 2024 / 09:30 PM GMT
Release Date Price: $0.301 (-5.35%)

Key Points

Positve
  • Panbela Therapeutics Inc (PBLA) secured a $12 million strategic loan commitment from Napp Capital, which represents both financial backing and a potential clinical alliance.
  • The company's lead program, the phase three Aspire global clinical trial, is progressing well with a faster than expected enrollment rate.
  • Panbela Therapeutics Inc (PBLA) has observed a notably lower event rate in their Aspire trial, potentially indicating better patient outcomes.
  • The company is advancing multiple clinical programs, including a phase two trial in castration-resistant metastatic prostate cancer and a type one diabetes trial.
  • Panbela Therapeutics Inc (PBLA) continues to expand its clinical pipeline with promising preclinical data and collaborations with prestigious institutions like MD Anderson Cancer Center.
Negative
  • Panbela Therapeutics Inc (PBLA) reported a net loss of $7.2 million for the quarter, indicating ongoing financial challenges.
  • The company's total cash as of September 30th, 2024, was only approximately $142,000, highlighting liquidity concerns.
  • Current liabilities significantly exceed current assets, with liabilities at $20.1 million compared to assets of $5.2 million.
  • The $12 million loan from Napp Capital has a six-month maturity and high-interest rate, which may pressure the company's financials.
  • Panbela Therapeutics Inc (PBLA) is still pursuing a new listing on a national securities exchange, indicating potential challenges in meeting listing requirements.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PBLA.PK - Panbela Therapeutics Inc
Q3 2024 Panbela Therapeutics Inc Earnings Call
Nov 14, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Panbela Therapeutics third quarter, 2024 earnings call.

At this time, all participants are on a listen-only mode and a question and answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press star zero on your telephone keypad.

Please note this conference is being recorded.

Joining me on today's call are Jennifer Simpson, Chief Executive Officer and Sue Horvath Chief Financial Officer.

Before we begin, please note that statements made on this call that are not historical facts may be considered forward-looking statements, risks and uncertainties that could cause actual results
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.